271 related articles for article (PubMed ID: 17205486)
1. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.
Hope WW; Kruhlak MJ; Lyman CA; Petraitiene R; Petraitis V; Francesconi A; Kasai M; Mickiene D; Sein T; Peter J; Kelaher AM; Hughes JE; Cotton MP; Cotten CJ; Bacher J; Tripathi S; Bermudez L; Maugel TK; Zerfas PM; Wingard JR; Drusano GL; Walsh TJ
J Infect Dis; 2007 Feb; 195(3):455-66. PubMed ID: 17205486
[TBL] [Abstract][Full Text] [Related]
2. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
3. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.
Hope WW; Petraitis V; Petraitiene R; Aghamolla T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2010 Nov; 54(11):4879-86. PubMed ID: 20713673
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.
Al-Nakeeb Z; Petraitis V; Goodwin J; Petraitiene R; Walsh TJ; Hope WW
Antimicrob Agents Chemother; 2015 May; 59(5):2735-45. PubMed ID: 25712363
[TBL] [Abstract][Full Text] [Related]
5. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
6. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
8. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.
McCulloch E; Ramage G; Rajendran R; Lappin DF; Jones B; Warn P; Shrief R; Kirkpatrick WR; Patterson TF; Williams C
J Clin Pathol; 2012 Jan; 65(1):83-6. PubMed ID: 22049217
[TBL] [Abstract][Full Text] [Related]
9. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
11. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.
Sionov E; Mendlovic S; Segal E
J Antimicrob Chemother; 2005 Sep; 56(3):594-7. PubMed ID: 16006446
[TBL] [Abstract][Full Text] [Related]
12. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
Moosa MY; Alangaden GJ; Manavathu E; Chandrasekar PH
J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
15. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.
Ben-Ami R; Albert ND; Lewis RE; Kontoyiannis DP
J Infect Dis; 2013 Apr; 207(7):1066-74. PubMed ID: 23303813
[TBL] [Abstract][Full Text] [Related]
16. The effect of antifungal agents and human monocytes on in vitro galactomannan release by Aspergillus spp. in liquid culture medium.
Winn RM; Warris A; Gaustad P; Abrahamsen TG
APMIS; 2007 Dec; 115(12):1364-9. PubMed ID: 18184406
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
18. Standardization of an experimental murine model of invasive pulmonary aspergillosis.
Sheppard DC; Graybill JR; Najvar LK; Chiang LY; Doedt T; Kirkpatrick WR; Bocanegra R; Vallor AC; Patterson TF; Filler SG
Antimicrob Agents Chemother; 2006 Oct; 50(10):3501-3. PubMed ID: 17005844
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
Lestner JM; Howard SJ; Goodwin J; Gregson L; Majithiya J; Walsh TJ; Jensen GM; Hope WW
Antimicrob Agents Chemother; 2010 Aug; 54(8):3432-41. PubMed ID: 20439615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
